Recent advances in blood-based biomarkers allow classification of individuals according to amyloid/tau (A/T) pathology, neurodegeneration (N), and microglial activation, thus enabling characterisation of AD-related pathology based on blood tests.28, 29, 30 The blood N-glycome or glycoproteome may provide additional information on AD subtype and pathological processes. Here, MAPT is linked to Alzheimer disease.